Comparative analysis of testing methods used for the detection of PTDs in the KMT2A/MLL gene

In this AMP 2022 session, Dr. Capo-Chichi shares his experience evaluating KMT2A- PTDs detection utilising three technologies; the SureSeq™ NGS panel with KMT2A specific probes engineered by OGT, an MLPA assay, and Optical Genome Mapping (OGM). SureSeq Myeloid NGS panels coupled with OGT’s Interpret NGS software provide robust detection of KMT2A-PTDs.
Disclaimer: This presentation is intended for educational purposes only and does not replace independent professional judgment. Statements of fact and opinions expressed are those of the presenters individually and, unless expressly stated to the contrary, are not the opinion or position of the Oxford Gene Technology Group (OGT). OGT does not endorse or approve, and assumes no responsibility for, the content, accuracy or completeness of the information presented.